News
NRSNW
0.5226
+30.65%
0.1226
NEUROSENSE REGAINS COMPLIANCE WITH NASDAQ'S MINIMUM EQUITY REQUIREMENT
Reuters · 5d ago
Weekly Report: what happened at NRSNW last week (1230-0103)?
Weekly Report · 5d ago
Weekly Report: what happened at NRSNW last week (1223-1227)?
Weekly Report · 12/30/2024 09:58
NEUROSENSE THERAPEUTICS LTD: CO WOULD RETAIN FULL RIGHTS TO PRIMEC IN OTHER KEY TERRITORIES
Reuters · 12/23/2024 14:00
Weekly Report: what happened at NRSNW last week (1216-1220)?
Weekly Report · 12/23/2024 10:01
NEUROSENSE THERAPEUTICS 9M OPERATING INCOME USD -8.131 MILLION
Reuters · 12/18/2024 15:26
Weekly Report: what happened at NRSNW last week (1209-1213)?
Weekly Report · 12/16/2024 10:01
NEUROSENSE THERAPEUTICS LTD: PLANS TO SUBMIT FINAL PROTOCOL TO FDA DURING FIRST HALF OF 2025
Reuters · 12/11/2024 14:25
Weekly Report: what happened at NRSNW last week (1202-1206)?
Weekly Report · 12/09/2024 10:00
NEUROSENSE THERAPEUTICS ANNOUNCES $5 MILLION PRIVATE PLACEMENT AT PREMIUM TO MARKET PRICE
Reuters · 12/02/2024 13:30
Weekly Report: what happened at NRSNW last week (1125-1129)?
Weekly Report · 12/02/2024 10:00
Weekly Report: what happened at NRSNW last week (1118-1122)?
Weekly Report · 11/25/2024 09:57
BRIEF-Neurosense Therapeutics Files For Offering Of Up To 10 Million Ordinary Shares
Reuters · 11/19/2024 22:25
Weekly Report: what happened at NRSNW last week (1111-1115)?
Weekly Report · 11/18/2024 09:55
Weekly Report: what happened at NRSNW last week (1104-1108)?
Weekly Report · 11/11/2024 10:01
Weekly Report: what happened at NRSNW last week (1028-1101)?
Weekly Report · 11/04/2024 10:00
NEUROSENSE: IN CANADA, PLANS TO SUBMIT DOSSIER IN Q2 2025, WITH REGULATORY DECISION ON COMMERCIALIZATION EXPECTED BY Q1 2026
Reuters · 10/28/2024 12:31
Weekly Report: what happened at NRSNW last week (1021-1025)?
Weekly Report · 10/28/2024 09:57
Neurosense Therapeutics Ltd: Report of foreign issuer
Press release · 10/25/2024 12:10
Weekly Report: what happened at NRSNW last week (1014-1018)?
Weekly Report · 10/21/2024 09:56
More
Webull provides a variety of real-time NRSNW stock news. You can receive the latest news about Neurosense Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NRSNW
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease